Table 1.
Active clinical trials investigating the activity of IDO inhibitors in advanced cancer.
| Agent | Regimen | Disease | Sponsor | ClinicalTrials.gov Identifier | Phase of development | Reference |
|---|---|---|---|---|---|---|
| NLG-919 | Monotherapy | Advanced solid tumors | New link genetics | NCT02048709 | I | (72) |
| Indoximod | Temozolomide | Glioblastoma multiforme | New link genetics | NCT02052648 | I/II | (75) |
| Indoximod | Docetaxel | Breast cancer | New link genetics | NCT01792050 | II | (76) |
| Indoximod | Sipuleucel-T | Prostate cancer | New link genetics | NCT01560923 | II | (77) |
| Indoximod | Ipilimumab | Melanoma | New link genetics | NCT02073123 | I/II | (78) |
| INCB024360 | Ipilimumab | Melanoma | Incyte Corp. | NCT01604889 | I/II | (74) |
| INCB024360 | Pembrolizumab | Lung cancer and other solid tumors | Incyte Corp./Merck & Co. | NCT02178722 | I/II | clinicalTrials.gov |
| INCB024360 | Anti-DEC-205/NY-ESO-1 vaccine and poly-ICLC | Ovarian, fallopian, peritoneal cancers | Fred Hutchinson Cancer Center/CITN/Celldex Therapeutics | NCT02166905 | I/II | clinicalTrials.gov |
| INCB024360 | MELITAC multipeptide vaccine | Melanoma | Fred Hutchinson Cancer Research Center/CITN/Incyte Corp. | NCT01961115 | II | clinicalTrials.gov |
Ipilimumab, anti-CTLA-4 monoclonal antibody (Bristol-Myers Squibb). Pembrolizumab, anti-PD-1 monoclonal antibody (Merck & Co.). anti-DEC-205-NY-ESO-1, DC-targeted antibody-peptide fusion vaccine (CDX-1401, Celldex Therapeutics). Poly-ICLC, polyinosinic-polycytidylic acid and poly-l-lysine double-stranded RNA TLR3 agonist (Oncovir, Inc.). MELITAC multipeptide vaccine, emulsion of a mixture of 12 class I MHC-restricted melanoma peptides (University of Virginia), CITN, Cancer Immunotherapy Network.